HomeCONGRESSInternational Congresses

International Congresses

View Category
Structural heart disease

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...
Dr. Juan Manuel Pérez -
Learn More
Acute coronary syndromes

TCT 2025 | VICTORY Trial: super-high-pressure NC balloon vs. IVL in severely calcified coronary lesions

Recent studies such as ECLIPSE have demonstrated the safety of non-compliant (NC) balloons compared with orbital atherectomy,...
Dr. Omar Tupayachi -
Learn More
Calcified Lesions

TCT 2025 | ShortCUT Trial: intravascular lithotripsy vs. cutting balloon in calcified coronary lesions

Coronary calcification is a major determinant of PCI complexity and failure. Balloon-based plaque-modifying devices —such as cutting...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

TCT 2025 | SELUTION4ISR: sirolimus-eluting balloon for in-stent restenosis

In-stent restenosis (ISR) continues to be a relevant clinical challenge in contemporary PCI practice. In the DES...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

TCT 2025 | SELUTION DeNovo: sirolimus-eluting balloon vs. stent in de novo coronary lesions

The use of drug-eluting stents (DES) remains the standard strategy in most percutaneous coronary intervention (PCI) procedures....
Dr. Omar Tupayachi -
Learn More
ESC 2025

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications...
solaci -
Learn More
ESC 2025

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More